logo
  • Home
  • Technologies
    • Live Cell Encapsulation
    • Research & Development
    • Cancer
    • Diabetes
    • Cannabinoids
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
    • International Diabetes Consortium
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact

All SEC Filings

Navigation Toggle Navigation
  • Overview
  • News / Events
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
Filter Filings:
Date Form Description Docs XBRL Pages
11/22/21 424B3 Prospectus filed pursuant to Rule 424(b)(3) HTML PDF 23
11/17/21 EFFECT Notice of Effectiveness HTML PDF 1
11/15/21 CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission. HTML PDF 1
11/15/21 UPLOAD SEC-generated letter
Related Documents
TEXT-EXTRACT
PDF 1
11/08/21 S-3 Registration statement for specified transactions by certain issuers
Related Documents
EX-5.1
EX-23.1
HTML PDF 33
11/04/21 SC 13D Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities HTML PDF 14
09/14/21 10-Q Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF XBRL Viewer XLS XBRL Files 25
09/10/21 8-K Current report filing
Related Documents
EX-99.1
HTML PDF XBRL Viewer XLS XBRL Files 27
09/03/21 3 Initial statement of beneficial ownership of securities HTML PDF 2
09/01/21 D Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act. HTML PDF 6
RSS
  • << Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...32
  • Next >>

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites May 23, 2022
  • PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes April 27, 2022